Treatment and prevention of early disease before and after exposure to COVID-19 using hydroxychloroquine: A protocol for exploratory re-analysis of age and time-nuanced effects: Update based on initial dataset review

REVISION SUMMARY

• Version 1.29/27/20Registered: OSF https://osf.io/fqtnwDOI: doi.org/10.17605/OSF.IO/FQTNW In reviewing the released PEP data, we discovered that shipping times (up to 3.5 days) were not considered in the published analysis. Requesting additional data, our re-stratification suggest that HCQ received within 3 days may reduce illness by as much as 65%. Before proceeding, this finding necessitates protocol revision, further data clarification, and the inclusion of companion studies sharing this and/or related issues. Version 1.2a9/27/20Submitted to medrxiv i)Per medrxiv request, detailed protocol rationale moved to supplement, with summary in new section ‎1.3.1. ii)Abstract and Summary shortened iii)Correction of typos, OSF url and doi information iv)Requested changes annotated in v1.2 revision list Revision list for v1.2 (annotated for medrxiv changes in v1.2a) a)Title change from: [Preventing disease after exposure to COVID-19 using hydroxychloroquine: A summary of a protocol for exploratory re-analysis of age and time-nuanced effects.] b)Plain language summary added. Abstract revised accordingly. c)Scope of protocol widened to include PrEP and Treatment studies, based on subject overlap and common issues between the three companion studies.1-3 The possible inclusion of a second13 Spanish study, for early treatment of COVID-19 also now added. d)Registration details for v1.1 e)Co-author MZ added (‎1.2) f)Relationship to Watanabe analysis.6 (‎1.3, now in Supplement). g)Sub headings added for Background section. (‎1.3). h)Discussion of findings related to treatment lag (summary in ‎1.3.1, expanded in Supplement). i)Discussion of missing data from censored subjects (summary in ‎1.3.1, expanded in Supplement). j)Revised HCW estimate from CDC (‎1.3, moved to Supplement). k)Discussion of possible negative effects of folate as placebo (summary in ‎1.3.1, expanded in Supplement). l)Discussion of companion study on pre-exposure prophylaxis.1 (summary in ‎1.3.1, expanded in Supplement). m)Relationship to companion study on early treatment (summary in ‎1.3.1, expanded in Supplement). n)Revise aims, objectives etc. to include widened scope of companion studies ( ‎1.3.1, 1.4). o)Revised time stratification based on new data on shipping times (summary in ‎1.3.1, expanded in Supplement). p)First data access (8/20/20) (‎3.1) q)Update on dataset per QC check and dataset clarifications received to 9/18/20 (‎3.1). r)Analysis for effect of folate on COVID-19, sub stratification for gender (‎4.1). s)Chi square test added (‎5.1) t)Revised missing data, definition of Responding Population (‎5.5) u)Per protocol analysis added (‎5.5) v)Update privacy issues (‎6.6) w)Record clarifying dataset: https://osf.io/tsmp6/